Needham Raises Price Target on RxSight to $66 From $54, Adds Stock to Conviction List, Keeps Buy Rating

07:20 AM EDT, 08/20/2024 (MT Newswires) -- RxSight (RXST) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $54 to $75.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)